Shanghai MicroPort MedBot (Group) Future Growth
Future criteria checks 2/6
Shanghai MicroPort MedBot (Group) is forecast to grow earnings and revenue by 49.1% and 69.1% per annum respectively. EPS is expected to grow by 57.4% per annum. Return on equity is forecast to be -7.6% in 3 years.
Key information
49.1%
Earnings growth rate
57.4%
EPS growth rate
| Medical Equipment earnings growth | 35.3% |
| Revenue growth rate | 69.1% |
| Future return on equity | -7.6% |
| Analyst coverage | Low |
| Last updated | 08 Apr 2024 |
Recent future growth updates
Recent updates
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252) Analysts Just Trimmed Their Revenue Forecasts By 58%
Apr 12
Is Shanghai MicroPort MedBot (Group) (HKG:2252) Using Debt Sensibly?
Mar 29Is Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252) Expensive For A Reason? A Look At Its Intrinsic Value
Oct 24We're Not Very Worried About Shanghai MicroPort MedBot (Group)'s (HKG:2252) Cash Burn Rate
May 19Here's Why We're Not Too Worried About Shanghai MicroPort MedBot (Group)'s (HKG:2252) Cash Burn Situation
Feb 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,403 | -98 | N/A | -17 | 3 |
| 12/31/2025 | 697 | -513 | -674 | -448 | 4 |
| 12/31/2024 | 225 | -686 | -850 | -457 | 3 |
| 12/31/2023 | 105 | -1,012 | -634 | -568 | N/A |
| 9/30/2023 | 86 | -1,116 | -895 | -788 | N/A |
| 6/30/2023 | 68 | -1,220 | -1,155 | -1,008 | N/A |
| 3/31/2023 | 45 | -1,180 | -1,124 | -953 | N/A |
| 12/31/2022 | 22 | -1,140 | -1,093 | -898 | N/A |
| 9/30/2022 | 12 | -970 | -944 | -745 | N/A |
| 6/30/2022 | 3 | -800 | -794 | -591 | N/A |
| 3/31/2022 | 3 | -691 | -734 | -566 | N/A |
| 12/31/2021 | 2 | -583 | -674 | -540 | N/A |
| 9/30/2021 | 1 | -489 | -507 | -424 | N/A |
| 6/30/2021 | N/A | -396 | -340 | -308 | N/A |
| 3/31/2021 | N/A | -299 | -229 | -206 | N/A |
| 12/31/2020 | N/A | -203 | -118 | -103 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2252 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2252 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2252 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2252's revenue (69.1% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2252's revenue (69.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2252 is forecast to be unprofitable in 3 years.